GeoVax Labs (GOVX) Projected to Post Quarterly Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect GeoVax Labs to post earnings of ($0.79) per share and revenue of $2.38 million for the quarter.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $1.73 on Wednesday. The business’s 50-day moving average is $1.97 and its 200-day moving average is $2.59. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research note on Thursday, February 27th. Finally, Alliance Global Partners assumed coverage on GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, GeoVax Labs currently has an average rating of “Buy” and an average target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.